 Sanofi and Principia Biopharma Inc. NASDAQ: PRNB, a late-stage biopharmaceutical company focused on developing treatments for immune-mediated diseases, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Principia for 100 per share in cash, which represents an aggregate equity value of approximately 3.68 billion on a fully diluted basis. The Sanofi and Principia Boards of Directors unanimously approved the transaction. 